London, UK, 14 December 2015: BTG plc (LSE: BTG), the specialist healthcare company, announces it has received 510k clearance from the US Food and Drug Administration for LC Bead LUMI™, the first commercially available radiopaque embolic bead, for the embolisation of hypervascular tumours and arteriovenous malformations (AVMs).

LC Bead LUMI™ is a next generation development of LC Bead®, the market leading embolic bead, that enables real-time visible confirmation of bead location during embolisation. This has the potential to provide interventional radiologists increased control, enabling real-time adjustments to optimise patient treatment.The lasting radiopacity of LC Bead LUMI™ means they will also be visible in follow-up scans, allowing precise evaluation of the completeness of tumour treatment.

Louise Makin, BTG’s CEO, commented: “LC Bead LUMI™ reinforces our leadership in embolisation technology and our focus on bringing to market innovative products that better serve specialist physicians and their patients. We look forward to securing regulatory clearances for additional radiopaque bead products in other markets.”

About BTG

BTG is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of liver tumours, severe blood clots, varicose veins and advanced emphysema, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today’s most complex healthcare challenges. To learn more about BTG, please visit: www.btgplc.com.